Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: September 22, 2009
Zoonotic diseases can threaten both health and economies around the world. Unfortunately, for several reasons, disease surveillance in the United States and abroad is not very effective in alerting officials to emerging zoonotic diseases. In response to this challenge, the Institute of Medicine and National Research Council’s 2009 report Sustaining Global Surveillance and Response to Emerging Zoonotic Diseases calls for the United States to take the lead, working with global health organizations to establish a global surveillance system that better integrates the human and animal health sectors, resulting in improved early detection and response.
Released: August 26, 2009
Tuberculosis is one of the leading causes of death in the world today, with 4,500 people dying from the disease every day. Many cases of TB can be cured by available antibiotics, but some TB is resistant to multiple drugs--a major and growing threat worldwide. The Institute of Medicine’s Forum on Drug Discovery, Development, and Translation hosted a workshop on November 5, 2008, to address the mounting concern of drug-resistant TB. The session brought together a wide range of international experts to discuss what is known and not known about this growing threat, and to explore possible solutions.
Released: July 10, 2009
Smallpox was a devastating disease that plagued humankind throughout history. Its eradication in 1980 was a monumental achievement for the global health community. All acknowledged stocks of variola virus, the causative agent of smallpox, or materials that might contain the virus, have been transferred to two World Health Organization approved repositories. During the period since eradication, the World Health Assembly (WHA) has debated whether to retain or destroy these stocks of live variola virus. This question will be reconsidered in 2010. In anticipation of this decision, the IOM was asked to revisit the question of scientific needs for live variola virus.
Released: April 24, 2009
The American Society of Clinical Oncology (ASCO) predicts that by 0, there will be an 81 percent increase in people living with or surviving cancer but only a 14 percent increase in the number of practicing oncologists. As a result, there may be too few oncologists to meet the population’s need for cancer care. To help address the challenges in overcoming this potential crisis of cancer care, the National Cancer Policy Forum of the Institute of Medicine (IOM) convened the workshop “Ensuring Quality Cancer Care through the Oncology Workforce: Sustaining Care in the 21st Century” in , DC on October 20 and 21, 2008.
Released: April 09, 2009
Dr. Joshua Lederberg – scientist, Nobel laureate, visionary thinker, and friend of the Forum on Microbial Threats – died on February 2, 2008. It was in his honor that the Institute of Medicine’s Forum on Microbial Threats convened a public workshop on May 20-21, 2008, to examine Dr. Lederberg’s scientific and policy contributions to the marketplace of ideas in the life sciences, medicine, and public policy. The resulting workshop summary, Microbial Evolution and Co-Adaptation, demonstrates the extent to which conceptual and technological developments have, within a few short years, advanced our collective understanding of the microbiome, microbial genetics, microbial communities, and microbe-host-environment interactions.
Released: February 19, 2009
The process for developing new drug and biologic products is extraordinarily expensive and time-consuming—many consider the traditional model to be unsustainable. Although large pharmaceutical companies may be able to invest in the development of blockbuster drugs because they can expect a large return on their investment, these same organizations, when developing drugs to treat rare and neglected diseases, are unable to rely on such returns. On June 23, 2008, the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation held a public workshop, “Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies,” which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.
Released: February 06, 2009
For many years, concerns about bioterrorism and emerging infectious diseases have drawn attention to the need for strong surveillance systems. Experts are working to develop new and better ways to detect these biological threats as quickly as possible. One effort in this area is the Department of Homeland Security’s BioWatch program. To evaluate the effectiveness of the BioWatch program, the Institute of Medicine (IOM) and National Research Council (NRC) convened the Committee on Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System. This interim report contains no findings and recommendations, but outlines the committee’s initial progress.
Released: January 23, 2009
The NCI-sponsored cooperative groups have made important contributions to improving treatment for many types of cancer, including breast, ovarian, colorectal, and childhood cancers. Cooperative group research has been instrumental in establishing innovative treatments that improve outcomes and quality of life. Despite these successes, the Cooperative Group Program has faced a number of challenges that threaten its effectiveness. To address this problem, the National Cancer Policy Forum (NCPF) convened a workshop titled “Multi-Center Phase III Clinical Trials and NCI Cooperative Groups” in , DC, on July 1-2, 2008. The purpose of the workshop was to outline the challenges that the public clinical cancer research enterprise faces, and to identify possible solutions to these challenges.
Released: December 22, 2008
One of the biggest threats today is the uncertainty surrounding the emergence of a novel pathogen or the re-emergence of a known infectious disease that might result in disease outbreaks with great losses of human life and immense global economic consequences. In June 2008, the Institute of Medicine’s and National Research Council’s Committee on Achieving Sustainable Global Capacity for Surveillance and Response to Emerging Diseases of Zoonotic Origin convened a workshop that addressed the reasons for the transmission of zoonotic disease and explored the current global capacity for zoonotic disease surveillance.
Released: December 11, 2008
Colorectal cancer screening remains low, despite strong evidence that screening prevents deaths. With the aim to make recommended colorectal cancer screening more widespread, the workshop discussed steps to be taken at the clinic, community, and health system levels.